Alembic Pharmaceuticals gets USFDA final approval for Amlodipine and Atorvastatin Tablets Corporates · May 23, 2025
Alembic Pharmaceuticals shares drop 2% as Q4 net profit falls 11.9% YoY to Rs 156.89 crore Stock Market · May 6, 2025
Alembic Pharmaceuticals gets USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial Corporates · Apr 1, 2025
Alembic Pharmaceuticals receives form 483 with one procedural observation after US FDA inspection at Vadodara facility Corporates · Mar 7, 2025
Alembic Pharmaceuticals completes ANVISA GMP Audit for API-II Facility in Brazil Corporates · Dec 11, 2024
Alembic Pharmaceuticals receives tentative USFDA approval for olopatadine hydrochloride solution Corporates · Dec 4, 2024
Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules Corporates · Nov 11, 2024
Alembic Pharmaceuticals receives USFDA approval for Diltiazem Hydrochloride Extended-Release capsules Corporates · Oct 20, 2024
Alembic Pharmaceuticals hits 52-week high as its oncology formulations unit successfully completes USFDA inspection Stock Market · Oct 9, 2024
Alembic Pharmaceuticals successfully completes USFDA inspection at its Oncology Formulation Facility Corporates · Oct 9, 2024
Alembic Pharmaceuticals receives USFDA approval for Alcaftadine Ophthalmic Solution Corporates · Oct 4, 2024
Alembic Pharmaceuticals shares surge 3% after receiving USFDA final approval for Lamotrigine Extended-Release Tablets Stock Market · Oct 3, 2024